Barlow Wealth Partners
VRTX icon

Barlow Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Barlow Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16M Buy
31,947
+1,161
+4% +$594K 1.65% 29
2026
Q2 		$15.3M Buy
30,786
+375
+1% +$166K 1.66% 29
2026
Q1 		$13.4M Buy
30,411
+324
+1% +$151K 1.49% 27
2025
Q4 		$14M Buy
30,087
+207
+0.7% +$89.2K 1.51% 29
2025
Q3 		$12.7M Sell
29,880
-21,078
-41% -$8.81M 1.42% 30
2025
Q2 		$23.3M Buy
50,958
+865
+2% +$399K 2.79% 13
2025
Q1 		$24.7M Buy
50,093
+383
+0.8% +$178K 3.25% 8
2024
Q4 		$21.1M Buy
49,710
+2,138
+4% +$991K 2.67% 11
2024
Q3 		$21.3M Buy
47,572
+563
+1% +$270K 2.79% 9
2024
Q2 		$23.1M Buy
47,009
+796
+2% +$346K 3.19% 7
2024
Q1 		$18.3M Buy
46,213
+1,247
+3% +$527K 2.49% 11
2023
Q4 		$18.3M Buy
+44,966
New +$16.6M 2.6% 9

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barlow Wealth Partners's VRTX Position: Q3 2026 in Review

Barlow Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q3 2026, buying an estimated $594K and bringing the position to 31,947 shares worth $16M. The position accounts for 1.65% of the portfolio, ranked #29.

Barlow Wealth Partners first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $24.7M in Q1 2025. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Barlow Wealth Partners held 31,947 shares of Vertex Pharmaceuticals worth $16M as of Q3 2026.
  • Barlow Wealth Partners bought 1,161 Vertex Pharmaceuticals shares in Q3 2026, an estimated $594K.
  • Vertex Pharmaceuticals made up 1.65% of Barlow Wealth Partners's portfolio in Q3 2026, its #29 holding.
  • Barlow Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Barlow Wealth Partners's Vertex Pharmaceuticals position peaked at $24.7M in Q1 2025.
  • 992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Barlow Wealth Partners's 13F filing for Q3 2026, filed 15 Oct 2026.